Clinical Trials Logo

FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma clinical trials

View clinical trials related to FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05538897 Recruiting - Clinical trials for Stage IV Uterine Corpus Cancer AJCC v8

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Start date: March 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial tests the safety, side effects, best dose, and effectiveness of the combination of ipatasertib with megestrol acetate to megestrol acetate alone in patients with endometrial cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Ipatasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Megestrol acetate lowers the amount of estrogen and also blocks the use of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. The combination of ipatasertib and megestrol acetate may be more effective in treating endometrial cancer than megestrol acetate alone.

NCT ID: NCT04604613 Recruiting - Clinical trials for FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

Prediction of Recurrence Among Low Risk Endometrial Cancer Patients

Start date: November 8, 2012
Phase:
Study type: Observational

This study investigates whether molecular testing can help to predict the risk of endometrial cancer coming back (recurrence) after treatment in patients diagnosed with low risk endometrial cancer and scheduled to have surgery to remove the uterus and/or cervix (hysterectomy). Having sentinel lymph node mapping performed may help researchers to see if the cancer has spread in patients with low risk endometrial cancer.

NCT ID: NCT04092270 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Start date: May 7, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back after a period of improvement (recurrent). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving peposertib and pegylated liposomal doxorubicin hydrochloride may work better in treating patients with ovarian cancer compared to pegylated liposomal doxorubicin hydrochloride alone.